As a GLP-1 receptor agonist, semaglutide suppresses appetite, delays stomach emptying, and stimulates insulin secretion.[1] While semaglutide was originally developed for patients with T2D as a glucose-lowering medication, clinical trials later demonstrated significant weight loss in patients taking semaglutide.[6] Additional studies also support semaglutides effectiveness in promoting weight loss for non-diabetics.[1,7,8] Wegovy is the only semaglutide medication approved by the U.S
Nature 429, 184187
By acknowledging these issues and exploring alternative models like Direct Primary Care, we can work towards a healthcare system that better serves both patients and providers
And FDA regulators agreed, saying later that the substances "present significant safety risks," because most have not been extensively tested in humans
Photosynth Res 89: 127140 HerrmannJM,RiemerJ (2010) The intermembrane space of mitochondria
If that sentence made you skeptical, goodyour skepticism is exactly what this article is here to address